SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• No clinically meaningful differences in the pharmacokinetics (PK) of amivantamab-vmjw were observed based on mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-89 mL/min). The effect of severe renal impairment (eGFR 15-29 mL/min) or end-stage renal disease (eGFR <15 mL/min) on amivantamab-vmjw PK has not been studied.²
• Please refer to RYBREVANT product labeling for additional information.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 10 February 2026.